US FDA approves sodium zirconium cyclosilicate for treatment of hyperkalaemia in patients with end-stage renal disease on stable hemodialysis

Approval is based on data from phase IIIb DIALIZE trial which showed that a significantly higher proportion of patients in the sodium zirconium cyclosilicate group (41.2%) met the primary endpoint and were classified as responders compared to patients in the placebo group (1%).

SPS commentary:

This product is currently not licensed for this indication in the UK.